E-Mail
IMAGE: A researcher at Calibr, the drug discovery division of Scripps Research, working in the high-throughput screening facility used to identify potential COVID-19 therapies. view more
Credit: Scripps Research
June 3, 2021 - LA JOLLA, CA Mining the world s most comprehensive drug repurposing collection for COVID-19 therapies, scientists have identified 90 existing drugs or drug candidates with antiviral activity against the coronavirus that s driving the ongoing global pandemic.
Among those compounds, the Scripps Research study identified four clinically approved drugs and nine compounds in other stages of development with strong potential to be repurposed as oral drugs for COVID-19, according to results published June 3 in the journal
E-Mail
LA JOLLA, CA Even before the COVID-19 pandemic, most people in the United States already had been sick with a coronavirus, albeit a far less dangerous one. That s because at least four coronaviruses in the same general family as SARS-CoV-2 cause the benign yet annoying illness known as the common cold.
In a new study that appears in
Nature Communications, scientists from Scripps Research investigated how the immune system s previous exposure to cold-causing coronaviruses impact immune response to COVID-19. In doing so, they discovered one cross-reactive coronavirus antibody that s triggered during a COVID-19 infection.
The findings will help in the pursuit of a vaccine or antibody treatment that works against most or all coronaviruses, says senior author Raiees Andrabi, PhD, an investigator in the Department of Immunology and Microbiology.